GSK has been enjoying regulatory momentum in recent months as it works to bring its antibody-drug conjugate (ADC) Blenrep back to markets around the globe. | As GSK's Blenrep makes its return to ...

UK-based ViiV Healthcare, the HIV specialist company majority owned by GSK, with Pfizer and Shionogi as shareholders, has announced data from the Phase IIIb VOLITION study.

GSK (GSK) stock in focus as the FDA staff raise safety concerns over Blenrep combo for multiple myeloma ahead of an AdCom ...

In a recent regulatory development, the Subject Expert Committee (SEC) under the Oncology division of the Central Drugs ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

The offering, the first IPO this year, attracted more than 32 billion dirhams ($3.5 bln) in demand for 500 million dirhams in shares. GSK seeks FDA nod for expanded use of RSV vaccine in adults ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug ...

The U.S. Food and Drug Administration’s staff reviewers raised safety concerns about GSK’s blood cancer drug on Tuesday. The FDA reviewers noted that when the ...

Aurobindo Pharma has been selected as one of the generic manufacturers under the expanded voluntary licensing agreement ...

Aurobindo Pharma has been selected as one of the generic manufacturers under the expanded voluntary licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare.